Pharma News

PF-07257876 by Pfizer for Non-Small Cell Lung Carcinoma: Likelihood of Approval


GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

PF-07257876 overview

PF-07257876 was under development for the treatment of non-small cell lung carcinoma, squamous cell carcinoma of the head and neck and ovarian cancer. It is a bi-specific antibody targets programmed cell death 1 ligand 1 (PD L1) and leukocyte surface antigen CD47 (CD47).

Pfizer overview

Pfizer discovers, develops, manufactures, and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, women’s health, cancer, inflammation, immune disorders, and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, individual provider offices, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa, and the Middle East. Pfizer is headquartered in New York, the US.

For a complete picture of PF-07257876’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 11 March 2023

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.




Source link
#PF07257876 #Pfizer #NonSmall #Cell #Lung #Carcinoma #Likelihood #Approval

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *